A combination of aspirin 75 mg once daily (OD) and the P2Y12 inhibitor ticagrelor
represents the current standard antiplatelet treatment for acute coronary syndromes (ACS) …

Aspirin and P2Y12 inhibitors remain commonly prescribed antiplatelet drugs in the treatment
of atherothrombotic conditions. Despite established benefits of dual antiplatelet therapy …

The discovery of the antiplatelet effect of low-dose aspirin led to the hugely successful
strategy of dual antiplatelet therapy in patients with acute coronary syndromes (ACS) …

Aspirin has been the cornerstone of antithrombotic therapy for the treatment of acute
coronary syndromes (ACS) for more than 3 decades (1), and along with a P2Y12 inhibitor …

Acute coronary syndromes (ACS) are most commonly, but not exclusively, precipitated by
atherosclerotic plaque rupture or erosion, leading to a platelet-driven thrombotic response …

Essentials• Strong P2Y 12 blockade may cause platelet inhibition that is only minimally
enhanced by aspirin.• We evaluated aspirin withdrawal on platelet reactivity in ticagrelor …

Importance The role of aspirin as part of antiplatelet regimens in acute coronary syndromes
(ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. Objective To …

ABSTRACT Introduction: A P2Y12 inhibitor plus aspirin is the most widely used antiplatelet
strategy to prevent adverse outcomes in the setting of atherothrombotic vascular disease …

2 Tantry and Gurbel Aspirin Desensitization completed the desensitization protocol were
discharged on 100-mg aspirin per day, and 69.4% were on dual antiplatelet therapy. The …

The addition of P2Y12 receptor inhibitors to aspirin therapy has substantially improved the
care of patients with acute coronary syndromes (ACS) and those undergoing percutaneous …